Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $6.06, for a total value of $101,002.02. Following the completion of the transaction, the insider directly owned 1,176,506 shares in the company, valued at approximately $7,129,626.36. This trade represents a 1.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.23, for a total value of $103,835.41.
• On Wednesday, April 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $5.99, for a total value of $99,835.33.

Xeris Biopharma Trading Down 1.2%

NASDAQ:XERS traded down $0.07 during trading hours on Tuesday, reaching $6.00. 1,406,991 shares of the stock were exchanged, compared to its average volume of 1,838,139. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The business has a 50-day moving average of $6.05 and a two-hundred day moving average of $6.62. Xeris Biopharma Holdings, Inc. has a twelve month low of $4.30 and a twelve month high of $10.08. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 100.00 and a beta of 0.85.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The company had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers lifted its holdings in Xeris Biopharma by 3.9% during the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after buying an additional 1,735 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Xeris Biopharma by 6.5% in the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after acquiring an additional 2,351 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in shares of Xeris Biopharma by 17.7% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock valued at $126,000 after acquiring an additional 2,420 shares during the last quarter. Finally, AlphaCentric Advisors LLC increased its holdings in shares of Xeris Biopharma by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after acquiring an additional 2,494 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research note on Monday, March 2nd. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.